Global Critical Care Therapeutics Market 2021-2025

世界の救命救急治療市場2021-2025:アルブミン、アンチトロンビン濃縮物、プロトロンビン複合体濃縮物、第XIII因子濃縮物、フィブリノーゲン濃縮物

◆タイトル:Global Critical Care Therapeutics Market 2021-2025
◆商品コード:IRTNTR46526
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2021年1月18日
◆ページ数:約120
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア太平洋、その他
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥270,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥432,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

テクナビオ社の本調査レポートでは、世界の救命救急治療市場について調査し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、医薬品クラス別(アルブミン、アンチトロンビン濃縮物、プロトロンビン複合体濃縮物、第XIII因子濃縮物、フィブリノーゲン濃縮物)分析、顧客状況、地域別状況、企業状況、企業分析などを掲載しております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析 
・世界の救命救急治療市場規模:医薬品クラス別(アルブミン、アンチトロンビン濃縮物、プロトロンビン複合体濃縮物、第XIII因子濃縮物、フィブリノーゲン濃縮物)
・顧客状況
・地域別状況
・企業状況
・企業分析

Global Critical Care Therapeutics Market 2021-2025
Technavio has been monitoring the critical care therapeutics market and it is poised to grow by $ 888.68 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on critical care therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the high demand for albumin in China and increasing surgical procedures. In addition, high demand for albumin in China is anticipated to boost the growth of the market as well.
The critical care therapeutics market analysis includes drug class segment and geographical landscapes.

Technavio’s critical care therapeutics market is segmented as below:
By Drug Class
• Albumin
• Antithrombin
• Prothrombin complex
• Factor XIII
• Fibrinogen

By Geographical Landscapes
• North America
• Europe
• Asia
• ROW

This study identifies growing preference for marketed products over alternative treatment options as one of the prime reasons driving the critical care therapeutics market growth during the next few years.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on critical care therapeutics market covers the following areas:
• Critical care therapeutics market sizing
• Critical care therapeutics market forecast
• Critical care therapeutics market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading critical care therapeutics market vendors that include Baxter International Inc., Bristol-Myers Squibb Co., CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the critical care therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/critical-care-therapeutics-market-industry-analysis
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

【資料の目次】

• Executive Summary
o Market Overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Fiver forces analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by drug class
o Market segments
o Comparison by Drug class
o Albumin – Market size and forecast 2020-2025
o Antithrombin concentrates – Market size and forecast 2020-2025
o Prothrombin complex concentrates – Market size and forecast 2020-2025
o Factor XIII concentrates – Market size and forecast 2020-2025
o Fibrinogen concentrates – Market size and forecast 2020-2025
o Market opportunity by Drug class
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o Asia – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity by geography
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Vendor landscape
o Landscape disruption
o Industry risks
o Competitive scenario
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Baxter International Inc.
o Bristol-Myers Squibb Co.
o CSL Ltd.
o Grifols SA
o Kedrion Spa
o LFB SA
o Novartis AG
o Octapharma AG
o Pfizer Inc.
o Takeda Pharmaceutical Co. Ltd.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibit
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Other1 – Market share 2020-2025 (%)
• 22: Comparison by Other1
• 23: Albumin – Market size and forecast 2020-2025 ($ million)
• 24: Albumin – Year-over-year growth 2020-2025 (%)
• 25: Antithrombin concentrates – Market size and forecast 2020-2025 ($ million)
• 26: Antithrombin concentrates – Year-over-year growth 2020-2025 (%)
• 27: Prothrombin complex concentrates – Market size and forecast 2020-2025 ($ million)
• 28: Prothrombin complex concentrates – Year-over-year growth 2020-2025 (%)
• 29: Factor XIII concentrates – Market size and forecast 2020-2025 ($ million)
• 30: Factor XIII concentrates – Year-over-year growth 2020-2025 (%)
• 31: Fibrinogen concentrates – Market size and forecast 2020-2025 ($ million)
• 32: Fibrinogen concentrates – Year-over-year growth 2020-2025 (%)
• 33: Market opportunity by Other1
• 34: Customer landscape
• 35: Market share by geography 2020-2025 (%)
• 36: Geographic comparison
• 37: North America – Market size and forecast 2020-2025 ($ million)
• 38: North America – Year-over-year growth 2020-2025 (%)
• 39: Europe – Market size and forecast 2020-2025 ($ million)
• 40: Europe – Year-over-year growth 2020-2025 (%)
• 41: Asia – Market size and forecast 2020-2025 ($ million)
• 42: Asia – Year-over-year growth 2020-2025 (%)
• 43: ROW – Market size and forecast 2020-2025 ($ million)
• 44: ROW – Year-over-year growth 2020-2025 (%)
• 45: Key leading countries
• 46: Market opportunity by geography ($ million)
• 47: Impact of drivers and challenges
• 48: Vendor landscape
• 49: Landscape disruption
• 50: Industry risks
• 51: Vendors covered
• 52: Market positioning of vendors
• 53: Baxter International Inc. – Overview
• 54: Baxter International Inc. – Business segments
• 55: Baxter International Inc. – Key offerings
• 56: Baxter International Inc. – Key customers
• 57: Baxter International Inc. – Segment focus
• 58: Bristol-Myers Squibb Co. – Overview
• 59: Bristol-Myers Squibb Co. – Product and service
• 60: Bristol-Myers Squibb Co. – Key offerings
• 61: Bristol-Myers Squibb Co. – Key customers
• 62: Bristol-Myers Squibb Co. – Segment focus
• 63: CSL Ltd. – Overview
• 64: CSL Ltd. – Business segments
• 65: CSL Ltd. – Key offerings
• 66: CSL Ltd. – Key customers
• 67: CSL Ltd. – Segment focus
• 68: Grifols SA – Overview
• 69: Grifols SA – Business segments
• 70: Grifols SA – Key offerings
• 71: Grifols SA – Key customers
• 72: Grifols SA – Segment focus
• 73: Kedrion Spa – Overview
• 74: Kedrion Spa – Product and service
• 75: Kedrion Spa – Key offerings
• 76: Kedrion Spa – Key customers
• 77: Kedrion Spa – Segment focus
• 78: LFB SA – Overview
• 79: LFB SA – Product and service
• 80: LFB SA – Key offerings
• 81: LFB SA – Key customers
• 82: LFB SA – Segment focus
• 83: Novartis AG – Overview
• 84: Novartis AG – Business segments
• 85: Novartis AG – Key offerings
• 86: Novartis AG – Key customers
• 87: Novartis AG – Segment focus
• 88: Octapharma AG – Overview
• 89: Octapharma AG – Product and service
• 90: Octapharma AG – Key offerings
• 91: Octapharma AG – Key customers
• 92: Octapharma AG – Segment focus
• 93: Pfizer Inc. – Overview
• 94: Pfizer Inc. – Business segments
• 95: Pfizer Inc. – Key offerings
• 96: Pfizer Inc. – Key customers
• 97: Pfizer Inc. – Segment focus
• 98: Takeda Pharmaceutical Co. Ltd. – Overview
• 99: Takeda Pharmaceutical Co. Ltd. – Product and service
• 100: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 101: Takeda Pharmaceutical Co. Ltd. – Key customers
• 102: Takeda Pharmaceutical Co. Ltd. – Segment focus
• 103: Currency conversion rates for US$
• 104: Research Methodology
• 105: Validation techniques employed for market sizing
• 106: Information sources
• 107: List of abbreviations



【掲載企業】

Baxter International Inc., Bristol-Myers Squibb Co., CSL Ltd., Grifols SA, Kedrion Spa, LFB SA, Novartis AG, Octapharma AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[世界の救命救急治療市場2021-2025:アルブミン、アンチトロンビン濃縮物、プロトロンビン複合体濃縮物、第XIII因子濃縮物、フィブリノーゲン濃縮物]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆